REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

C. Lepage (1) , L. Dahan (2) , J.-L. Legoux (3) , K. Le Malicot (4) , R. Guimbaud (5) , D. Tougeron (6) , A. Lievre (7) , N. Bouarioua (8) , C. Petorin (9) , M. Pavel (10) , I. Borbath (11) , C. Toumpanakis (12) , D. Smith (13) , M. Ducreux (14) , T. Walter (15)

1 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
2 TIMONE - Hôpital de la Timone [CHU - APHM]
3 CHRO - Centre Hospitalier Régional d'Orléans
4 Fédération Francophone de la Cancérologie Digestive, FFCD
5 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
6 CHU de Poitiers - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
7 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
8 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
9 CHU Clermont-Ferrand
10 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
11 Cliniques universitaires St Luc [Bruxelles]
12 Royal Free Hospital [London, UK]
13 CHU Bordeaux
14 Oncologie digestive
15 HCL - Hospices Civils de Lyon

Mots clés: Duodeno-pancreatic neuroendocrine tumours; Clinical trial; Maintenance

Domaines: Endocrinologie et métabolisme

C. Lepage, L. Dahan, J.-L. Legoux, K. Le Malicot, R. Guimbaud, et al.. REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors . The 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Mar 2017, Barcelone, Spain. pp.187 (J8). ⟨hal-01664217⟩